Efficacy Of Melatonin In The Treatment Of Endometriosis: A Phase II, Randomized, Double-blind, Placebo-controlled Trial
Notes for this study:
||The participants who took melatonin had an average serum BDNF of 20.46, versus placebo 25.94; this difference was significant at the P < 0.001 level.
|Number of Subjects
||18-29, 30-44, 45-64
40 Brazilian women with endometriosis-associated chronic pelvic pain (EACPP) were randomized to take 10mg melatonin or placebo for 8 weeks. The melatonin group self-reported significantly less: overall pain, pain during menstruation, pain during sex, and use of analgesics (primary outcomes). They also self-reported significantly less pain while urinating and defecating, and better sleep (secondary outcomes). The study also measured blood BDNF levels and found that they were significantly lower in the melatonin group.
Funding issues for this study: